Potential role of exosome-associated microRNA panels and in vivo environment to predict drug resistance for patients with multiple myeloma

Oncotarget

Volumn 7, Issue 21, 2016, Pages 30876-30891

  Zhang, Li ^a,b   Pan, Ling ^a   Xiang, Bing ^a   Zhu, Huanling ^a   Wu, Yu ^a   Chen, Meng ^a   Guan, Pujun ^a   Zou, Xingli ^c   Valencia, C Alexander ^d   Dong, Biao ^a   Li, Jianjun ^a   Xie, Liping ^a   Ma, Hongbing ^a   Wang, Fangfang ^a   Dong, Tian ^a   Shuai, Xiao ^a   Niu, Ting ^a   Liu, Ting ^a  

^a SICHUAN UNIVERSITY   (China)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c AFFILIATED HOSPITAL OF NORTH SICHUAN MEDICAL COLLEGE   (China)

^d UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Exosome; MicroRNA; Microvesicle; Myeloma; Resistance

Indexed keywords

BORTEZOMIB; C REACTIVE PROTEIN; CHOLESTEROL; LENALIDOMIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MICRORNA; MICRORNA 15A 5P; MICRORNA 16 5P; MICRORNA 17 5P; MICRORNA 20A 5P; NANOPARTICLE; THALIDOMIDE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; IMMUNOGLOBULIN LIGHT CHAIN; TUMOR MARKER;

ADULT; ARTICLE; CANCER CLASSIFICATION; CANCER STAGING; CANCER SURVIVAL; CELL FUNCTION; CELL STRUCTURE; CHOLESTEROL BLOOD LEVEL; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DOWN REGULATION; EXOSOME; FEMALE; GENE AMPLIFICATION; GENETIC SCREENING; HUMAN; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; MOLECULAR INTERACTION; MULTIPLE MYELOMA; OVERALL SURVIVAL; RISK FACTOR; RNA ANALYSIS; SURVIVAL RATE; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; BLOOD; CHROMOSOME 1; CHROMOSOME ABERRATION; DISEASE EXACERBATION; DRUG RESISTANCE; GENETICS; METABOLISM; MIDDLE AGED; PREDICTIVE VALUE; TUMOR MICROENVIRONMENT;

ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; BORTEZOMIB; C-REACTIVE PROTEIN; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 1; DISEASE PROGRESSION; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; EXOSOMES; FEMALE; GENE AMPLIFICATION; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; MALE; MICROARRAY ANALYSIS; MICRORNAS; MIDDLE AGED; MULTIPLE MYELOMA; PREDICTIVE VALUE OF TESTS; RISK FACTORS; THALIDOMIDE; TUMOR MICROENVIRONMENT;

EID: 84971519374     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.9021     Document Type: Article

References (40)

1. Kyle RA, Durie BG, Rajkumar SV, Landgren O, Blade J, Merlini G, Kröger N, Einsele H, Vesole DH, Dimopoulos M, San Miguel J, Avet-Loiseau H, Hajek R, et al. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia. 2010; 24:1121-1127.
2. Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K, Brown J, Drayson MT, Selby PJ. Medical Research Council Adult Leukaemia Working Party. Highdose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med. 2003; 348:1875-1883.
3. Kristinsson SY, Anderson WF, Landgren O. Improved longterm survival in multiple myeloma up to the age of 80 years. Leukemia. 2014; 28:1346-1348.
4. Turesson I, Velez R, Kristinsson SY, Landgren O. Patterns of Improved Survival in Patients With Multiple Myeloma in the Twenty-First Century: A Population-Based Study. J Clin Oncol. 2010; 28:830-834.
5. Kumar SK, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Pandey S, Kapoor P, Dingli D, Hayman SR, Leung N, Lust J, McCurdy A, Russell SJ, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia. 2014; 28: 1122-1128.
6. Hao M, Zhang L, An G, Meng H, Han Y, Xie Z, Xu Y, Li C, Yu Z, Chang H, Qiu L. Bone marrow stromal cells protect myeloma cells from bortezomib induced apoptosis by suppressing microRNA-15a expression. Leuk Lymphoma. 2011; 52:1787-1794.
7. Garrison LP, Neumann PJ, Erickson P, Marshall D, Mullins D. Using real-world data for coverage and payment decisions: The ISPOR real-world data task force report. Value Health. 2007; 10:326-335.
8. Smith AD, Roda D, Yap TA: Strategies for modern biomarker and drug development in oncology. J Hematol Oncol. 2014; 7:70.
9. Xu Zhang, Xiao Yuan, Hui Shi, Lijun Wu, Hui Qian, Wenrong Xu. Exosomes in cancer: small particle, big player. J Hematol Oncol. 2015; 8:83.
10. Srivatsava Naidu, Peter Magee, Michela Garofalo. MiRNAbased therapeutic intervention of cancer. J Hematol Oncol. 2015; 8:68.
11. Challagundla KB, Fanini F, Vannini I, Wise P, Murtadha M, Malinconico L, Cimmino A, Fabbri M. microRNAs in the tumor microenvironment: solving the riddle for a better diagnostics. Expert Rev Mol Diagn. 2014; 14:565-574.
12. Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011; 364:1046-1060.
13. Meads MB, Gatenby RA, Dalton WS. Environmentmediated drug resistance: a major contributor to minimal residual disease. Nat Rev Cancer. 2009; 9:665-674.
14. Graziani MS, Merlini G. Serum free light chain analysis in the diagnosis and management of multiple myeloma and related conditions. Expert Rev Mol Diagn. 2014; 14:55-66.
15. Larsen JT, Kumar SK, Dispenzieri A, Kyle RA, Katzmann JA, Rajkumar SV. Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma. Leukemia. 2013; 27:941-946.
16. Giarin MM, Giaccone L, Sorasio R, Sfiligoi C, Amoroso B, Cavallo F, Cipriani A, Palumbo A, Boccadoro M. Serum free light chain ratio, total kappa/lambda ratio, and immunofixation results are not prognostic factors after stem cell transplantation for newly diagnosed multiple myeloma. Clin Chem. 2009; 55:1510-1516.
17. Offidani M, Corvatta L, Polloni C, Piersantelli MN, Galieni P, Visani G, Alesiani F, Catarini M, Brunori M, Burattini M, Centurioni R, Ferranti M, Giuliodori L, et al. Serum C-reactive protein at diagnosis and response to therapy is the most powerful factor predicting outcome of multiple myeloma treated with thalidomide/anthracyclinebased therapy. Clin Lymphoma Myeloma. 2008; 8:294-299.
18. Zahlten-Hinguranage A, Goldschmidt H, Cremer FW, Egerer G, Moehler T, Witte D. Preoperative elevation of serum C-reactive protein is predictive for prognosis in myeloma bone disease after surgery. Br J Cancer. 2006; 95:782-787.
19. Yang J, Wezeman M, Zhang X, Lin P, Wang M, Qian J, Wan B, Kwak LW, Yu L, Yi Q. Human C-reactive protein binds activating Fcgamma receptors and protects myeloma tumor cells from apoptosis. Cancer cell. 2007; 12:252-265.
20. San Miguel J, Bladé J, Boccadoro M, Cavenagh J, Glasmacher A, Jagannath S, Lonial S, Orlowski RZ, Sonneveld P, Ludwig H. A practical update on the use of bortezomib in the management of multiple myeloma. Oncologist. 2006; 11:51-61.
21. http://www.ehealthme.com/ds/velcade/creactive+protein+increased.
22. http://factmed.com/report-VELCADE-causing-CREACTIVE%20PROTEIN%20INCREASED.php.
23. Sood R, Carloss H, Kerr R, Lopez J, Lee M, Druck M, Walters IB, Noga SJ. Retreatment with bortezomib alone or in combination for patients with multiple myeloma following an initial response to bortezomib. Am J Hematol. 2009; 84:657-660.
24. Petrucci MT, Giraldo P, Corradini P, Teixeira A, Dimopoulos MA, Blau IW, Drach J, Angermund R, Allietta N, Broer E, Mitchell V, Bladé J. A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma. Br J Haematol. 2013; 160: 649-659.
25. Keats JJ, Chesi M, Egan JB, Garbitt VM, Palmer SE, Braggio E, Van Wier S, Blackburn PR, Baker AS, Dispenzieri A, Kumar S, Rajkumar SV, Carpten JD, et al. Clonal competition with alternating dominance in multiple myeloma. Blood. 2012; 120:1067-1076
26. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanian R, Siegel D, Orlowski RZ, Kuter D, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003; 348:2609-2617.
27. Cavo M, Tacchetti P, Patriarca F, Petrucci MT, Pantani L, Galli M, Di Raimondo F, Crippa C, Zamagni E, Palumbo A, Offidani M, Corradini P, Narni F, et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet. 2010; 376:2075-2085.
28. Harousseau JL, Attal M, Leleu X, Troncy J, Pegourie B, Stoppa AM, Hulin C, Benboubker L, Fuzibet JG, Renaud M, Moreau P, Avet-Loiseau H. Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study. Haematologica. 2006; 91:1498-1505.
29. Sonneveld P, Schmidt-Wolf IG, van der Holt B, El Jarari L, Bertsch U, Salwender H, Zweegman S, Vellenga E, Broyl A, Blau IW, Weisel KC, Wittebol S, Bos GM, et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/GMMG-HD4 trial. J Clin Oncol. 2012; 30:2946-2955.
30. An G, Xu Y, Shi L, Shizhen Z, Deng S, Xie Z, Sui W, Zhan F, Qiu L. Chromosome 1q21 gains confer inferior outcomes in multiple myeloma treated with bortezomib but copy number variation and percentage of plasma cells involved have no additional prognostic value. Haematologica. 2014; 99:353-359.
31. Biran N, Malhotra J, Bagiella E, Cho HJ, Jagannath S, Chari A. Patients with newly diagnosed multiple myeloma and chromosome 1 amplification have poor outcomes despite the use of novel triplet regimens. Am J Hematol. 2014; 89:616-620.
32. Maiso P, Huynh D, Moschetta M, Sacco A, Aljawai Y, Mishima Y, Asara JM, Roccaro AM, Kimmelman AC, Ghobrial IM. Metabolic signature identifies novel targets for drug resistance in multiple myeloma. Cancer Res. 2015; 75:2071-2082.
33. Ng MC, So WY, Cox NJ, Lam VK, Cockram CS, Critchley JA, Bell GI, Chan JC. Genome-wide scan for type 2 diabetes loci in Hong Kong Chinese and confirmation of a susceptibility locus on chromosome 1q21-q25. Diabetes. 2004; 53:1609-1613.
34. Hao M, Zhang L, An G, Sui W, Yu Z, Zou D, Xu Y, Chang H, Qiu L. Suppressing miRNA-15a/-16 expression by interleukin-6 enhances drug-resistance in myeloma cells. J Hematol Oncol. 2011; 4:37
35. Sun CY, She XM, Qin Y, Chu ZB, Chen L, Ai LS, Zhang L, Hu Y. miR-15a and miR-16 affect the angiogenesis of multiple myeloma by targeting VEGF. Carcinogenesis. 2013; 34:426-435.
36. Chen L, Li C, Zhang R, Gao X, Qu X, Zhao M, Qiao C. miR-17-92 cluster microRNAs confers tumorigenicity in multiple myeloma. Cancer Lett. 2011; 309:62-70.
37. Rocci A, Hofmeister CC, Geyer S, Stiff A, Gambella M, Cascione L, Guan J, Benson DM, Efebera YA, Talabere T, Dirisala V, Smith EM, Omedè P, et al. Circulating miRNA markers show promise as new prognosticators for multiple myeloma. Leukemia. 2014; 28:1922-1926.
38. Wen-Tao Wang, Yue-Qin Chen. Circulating miRNAs in cancer: from detection to therapy. J Hematol Oncol. 2014; 7:86.
39. Hanfstein B, Shlyakhto V, Lauseker M, Hehlmann R, Saussele S, Dietz C, Erben P, Fabarius A, Proetel U, Schnittger S, Krause SW, Schubert J, Einsele H, et al. Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib. Leukemia. 2014; 28:1988-1992.
40. International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003; 121: 749-757.